ClinicalTrials.gg
RecruitingNCT06001255Updated Aug 20, 2024

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

A Phase 2 interventional study of HS-20093 in Metastasis Castration Resistant Prostate Cancer(mCRPC), sponsored by Hansoh BioMedical R&D Company. Recruiting at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
169th of 401
120 · median 90
Started
2024
with 44 others
Phase 2
111 of 485
57 open now
Primary completion
2024-12
later than 28 of 262 live
Registered
290th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 169th largest by planned enrollment of the 401 interventional ones that give a count, is one of 45 that started in 2024, is one of 111 in phase 2, reaches primary completion later than 28 of the 262 other live ones, and was the 290th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety and pharmacokinetics of HS-20093 in Chinese patients with metastasis Castration Resistant Prostate Cancer.

This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) of HS-20093 as a monotherapy in subjects with metastasis castration resistant prostate cancers (mCRPC) and other solid tumors.

Read the detailed description

This is a phase 2, open-label, multi-center study consisting of two parts: Phase 2a and 2b.

Phase 2a: The study will be conducted in the following two cohorts: Cohort 1: Patients with metastasis castration resistant prostate cancers who have progressed on or intolerant to standard therapies. Cohort 2: Other patients with advanced solid tumor if they have progressed on or intolerant to available standard therapies, or no standard or available curative therapy exists. All subjects will receive 8 mg/kg of HS-20093.

Phase 2b: The study will be conducted in patients with metastasis castration resistant prostate cancers who have progressed on or intolerant to standard therapies. Subjects will receive 8 mg/kg of HS-20093.

All patients will be carefully followed for adverse events during the study treatment and for 90 days after the last dose of HS-20093. Subjects will be permitted to continue therapy with assessments for progression if the product is well tolerated and sustained clinical benefit exists.

03

Conditions studied

  • Metastasis Castration Resistant Prostate Cancer(mCRPC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects eligible for inclusion in this study must meet all of the following criteria:

    1. Men or women greater than or equal to 18 years.
    2. Locally advanced or solid tumors confirmed by histology or cytology, for which standard treatment is invalid, unavailable or intolerable.
    3. At least one in accordance with 1.1.
    4. Agree to provide fresh .
    5. (ECOG) Performance Status of 0\~1.
    6. Estimated ≥ 12 weeks.
    7. Men or women should be using adequate measures throughout the study.
    8. Female subjects must not be pregnant at screening or have evidence of non-.
    9. Signed and dated Form.

Exclusion criteria

Exclusion Criteria:

  • Any of the following would exclude the subject from participation in the study:

    1. Treatment with any of the following:

      Previous or current treatment with B7-H3 targeted therapy. Any cytotoxic chemotherapy, agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093. Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093.

      Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093.

      Pleural or peritoneal effusion requiring clinical intervention. Pericardial effusion.

      Major surgery within 4 weeks prior to the first scheduled dose of HS-20093. Spinal cord compression or . Treatment with drugs that are predominantly strong inhibitors or inducers or sensitive substrates of , CYP2D6, P-gp or BCRP with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.

      Currently receiving drugs known to prolong or may cause torsade de pointe; or requiring treatment with these drugs during the study

    2. Patients with BRCA and ATM mutation.
    3. Any unresolved toxicities from prior therapy greater than Grade 2 according to (CTCAE) 5.0 with the exception of alopecia or neurotoxicity
    4. History of other primary .
    5. Inadequate bone marrow reserve or organ dysfunction.
    6. Evidence of cardiovascular risk.
    7. Severe, uncontrolled or active cardiovascular diseases.
    8. Severe or uncontrolled diabetes, including diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated value ≥ 7.5% in the screening period.
    9. Severe or poorly controlled hypertension.
    10. Bleeding symptoms with apparent clinical significance or obvious bleeding tendency within 1 months prior to the first dose of HS-20093
    11. Serious arteriovenous thrombosis events occurred within 3 months before the first dose
    12. Severe infections occurred within 4 weeks before the first dose
    13. Patients who have received continuous treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment, or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation
    14. The presence of active infectious diseases before the first dose such as , , tuberculosis, syphilis, or HIV infection, etc.
    15. Hepatic encephalopathy, hepatorenal syndrome, or Grade B or more severe cirrhosis
    16. Other moderate or severe urinary diseases that may interfere with the detection or treatment of drug-related urinary toxicity or may seriously affect urinary function.
    17. History of serious neuropathy or mental disorders.
    18. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
    19. Vaccination or of any level within 4 weeks prior to the first dose of HS-20093
    20. History of severe hypersensitivity reaction, severe infusion reaction or allergy to recombinant human or mouse derived proteins
    21. Hypersensitivity to any ingredient of HS-20093
    22. Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator.
    23. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    HS-20093

    Participants will receive HS-20093 at 8 mg/kg.

    Drug: HS-20093

Interventions

  • Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) determined by investigators

    Cohort 1(mCRPC): Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3 (PCWG3) \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\]. Cohort 2(Other advanced solid tumors):Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\].

    Time frame: From the first dose up to disease progression or withdrawal from study, which ever came first, assessed up to 24 months

Secondary outcomes

  1. Incidence and severity of adverse events (AEs).

    AE assessed by investigator exclusively related to subject's underlying disease or medical condition \[graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\]. Any untoward medical occurrence in a clinical study participant, whether or not considered related to the medicinal product. Incidence and severity of AEs are assessed according to vital signs, laboratory variables, physical examination, electrocardiogram, etc.

    Time frame: From the first dose through 90 days post end of treatment.

  2. Observed maximum plasma concentration (Cmax) of HS-20093.

    Cmax will be obtained following administration of the first dose of HS-20093 during the first cycle.

    Time frame: From pre-dose to 14 days after the first dose on Cycle 1 (each cycle is 21 days)

  3. Time to reach maximum plasma concentration (Tmax) of HS-20093 following the first dose.

    Tmax will be obtained following administration of the first dose of HS-20093 during the first cycle.

    Time frame: From pre-dose to 14 days after the first dose on Cycle 1 (each cycle is 21 days).

  4. Terminal half-life (T1/2) of HS-20093 following the first dose.

    Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

    Time frame: From pre-dose to 14 days after the first dose on Cycle 1 (each cycle is 21 days).

  5. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20093.

    Area under the plasma concentration versus time curve from time zero to the last sampling time when the concentration was no less than the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: From pre-dose to 14 days after the first dose on Cycle 1 (each cycle is 21 days).

  6. Percentage of participants with antibodies to HS-20093 in serum

    Serum samples were collected for the determination of anti-drug antibody (ADA) at designated time points.

    Time frame: From pre-dose to 90 days post end of treatment.

  7. ORR determined by Independent review committee (IRC)

    Cohort 1(mCRPC): Objective response rate (ORR) determined by IRC according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3 (PCWG3) Cohort 2(Other advanced solid tumors):Objective response rate (ORR) determined by IRC according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\].

    Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months

  8. Duration of response (DoR) determined by investigators and IRC according to RECIST 1.1 and PCWG3

    DoR is defined as the period from the first occurrence of CR or PR to progressive disease (PD) or death from any cause. If no PD or death after CR/PR, the cut-off date of progression-free survival (PFS) would be used \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\].

    Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months

  9. Disease control rate (DCR) determined by investigators and IRC according to RECIST 1.1 and PCWG3

    Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline (Day -28 to -1). DCR was evaluated by the number of participants with best overall response of CR, PR and stable disease (SD) \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks); SD shall be assessed at least 5 weeks after the first dose\].

    Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months

  10. Progression-free survival (PFS) determined by investigators and IRC according to RECIST 1.1 and PCWG3

    Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline (Day -28 to -1). PFS is defined as the time from first dose or random assignment (if any) to PD or death from any cause.

    Time frame: From the first dose or random assignment up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  11. Radiographic Progression-Free Survival (rPFS) determined by investigators and IRC according to RECIST 1.1 and PCWG3

    The rPFS is defined as the time from the date of randomization to the date of first documented progressive disease (PD) per Prostate Cancer Working Group 3 (PCWG3) or death from any cause, whichever occurs first.

    Time frame: From the first dose or random assignment up to disease progression, assessed up to 24 months.

  12. Overall survival (OS)

    OS is defined as the time from the first dose or random assignment (if any) to death from any cause.

    Time frame: From the first dose or random assignment up to death or withdrawal from study, whichever came first, assessed up to 24 months

  13. Prostate-specific Cancer Antigen (PSA) response rate

    PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.

    Time frame: From the first dose or random assignment up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  14. Time to PSA progression

    In participants with a decrease in PSA from baseline: ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later. In participants with no decrease in PSA from baseline: ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks.

    Time frame: From the first dose or random assignment up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

07

Study locations

15 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2024, 11 months after the start.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 11 months is below that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Jan 18, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06001255
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jan 18, 2024
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 20, 2024

Study contacts

Weijing Zhang
Contact
JJYIN555@163.com
86-21-64175590 ext. 88503

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risvutatug rezetecan

Start the discussion